Wisconsin Assembly Bill AB499

Wisconsin 2025-2026 Regular Session

• Introduced: 10/9/25
• Refer: 10/9/25
• Failed: 3/23/26

Caption

An Act to create 49.45 (49m) (e) and 632.854 of the statutes; Relating to: coverage of nonopioid drug alternatives for the treatment and management of pain.

Impact

The introduction of AB499 represents a significant shift in state healthcare policy, particularly in the context of the ongoing opioid crisis. By promoting the use of nonopioid treatments, the bill seeks to limit the reliance on opioids, potentially reducing prescription rates and dependency issues associated with these drugs. The bill also prohibits healthcare plans from implementing more restrictive measures on nonopioid medications than those applied to opioids, which could enhance patient access to alternative treatments and reshape prescribing behaviors among healthcare providers.

Summary

Assembly Bill 499 aims to establish comprehensive regulations surrounding the coverage and access to nonopioid alternatives for pain management in healthcare plans across Wisconsin. This bill mandates that health care insurance providers, including self-insured governmental plans, must develop a pain management access plan that guarantees coverage for a variety of nonopioid treatment options. Specifically, it requires plans to include at least two FDA-approved alternative prescription medications and three nonpharmacological treatment modalities, all aimed at effectively managing pain without the use of opioids.

Contention

While proponents of AB499 advocate for a proactive approach to pain management that prioritizes safety and efficacy, some stakeholders express concern regarding its potential consequences. Critics raise questions about how this legislation could impact pharmaceutical companies and the availability of certain treatments. Furthermore, there's apprehension regarding the financial implications for insurance providers and whether such mandates might lead to increased costs for consumers or lower overall care quality if alternatives are not adequately effective for all patients.